利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.03 秒)

    DIFFERENTIAL DIAGNOSIS OF ECZEMA AND PSORIASIS
    4.
    发明申请
    DIFFERENTIAL DIAGNOSIS OF ECZEMA AND PSORIASIS 审中-公开
    EC MA。。。。。。。。。。。。。。。。。。。

    公开(公告)号：US20170037476A1

    公开(公告)日：2017-02-09

    申请号：US15304364

    申请日：2015-04-15

    申请人： HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) ,  KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN

    发明人： Kilian EYERICH ,  Carsten SCHMIDT-WEBER ,  Bettina KNAPP

    IPC分类号： C12Q1/68 ,  G01N33/68

    CPC分类号： C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/6881 ,  G01N2800/205

    摘要： The present invention relates to a method of diagnosing eczema and/or psoriasis, wherein said method differentiates between eczema and psoriasis, and comprises determining the expression of at least two markers in a sample taken from an individual, wherein said at least two markers are selected from CCL27, NOS2, IL36G, KLK13, SOST, NPTX1, PLA2G4D, GDA, IL36A, TGM1, CLEC4G, IL13, TCN1, TMPRSS11D and RHCG, provided that said at least two markers consist of or comprise (a) CCL27 and NOS2; (b) CCL27 and KLK13; (c) IL36G and KLK13; (d) CCL27 and IL36G; (e) NOS2 and IL36G; (f) NOS2 and KLK13; (g) SOST; or (h) NPTX1; and assessing on the basis of the expression of said at least two markers whether the individual is afflicted with eczema and/or psoriasis.

    摘要翻译： 本发明涉及一种诊断湿疹和/或牛皮癣的方法，其中所述方法区分湿疹和牛皮癣，并且包括测定取自个体的样品中至少两种标记物的表达，其中选择所述至少两种标记物 只要所述至少两个标记由（a）CCL27和NOS2组成或包含（a）CCL27，NOS2，IL36G，KLK13，SOST，NPTX1，PLA2G4D，GDA，IL36A，TGM1，CLEC4G，IL13，TCN1，TMPRSS11D和RHCG。 （b）CCL27和KLK13; （c）IL36G和KLK13; （d）CCL27和IL36G; （e）NOS2和IL36G; （f）NOS2和KLK13; （g）SOST; 或（h）NPTX1; 并且基于所述至少两个标记的表达来评估个体是否患有湿疹和/或牛皮癣。

    Medical/surgical implant
    7.
    发明授权
    Medical/surgical implant 有权

    公开(公告)号：US10799336B2

    公开(公告)日：2020-10-13

    申请号：US15509550

    申请日：2015-09-09

    申请人： Klinikum rechts der Isar der Technischen Universität München

    发明人： Dietmar Werner Hutmacher ,  Jan-Thorsten Schantz ,  Paul Severin Wiggenhauser ,  Mohit Prashant Chhaya

    IPC分类号： A61F2/12 ,  A61L27/18 ,  A61L27/44 ,  A61L27/56 ,  A61L27/28 ,  A61L27/50 ,  A61L27/54 ,  A61L27/58 ,  A61F2/00

    摘要： The present invention relates to the field of implants. In particular, the present invention relates to an implant for tissue reconstruction which comprises a scaffold structure that includes a void system for the generation of prevascularized connective tissue with void spaces for cell and/or tissue transplantation. Moreover, the present invention relates to a method of manufacturing such an implant, to the internal architecture of such an implant, to a removal tool for mechanical removal of space-occupying structures from such an implant, to a kit comprising such an implant and such a removal tool, to a removal device for the removal of superparamagnetic or ferromagnetic space-occupying structures from such an implant, as well as to a guiding device for providing feedback to a surgeon during the procedure of introducing transplantation cells into the void spaces generated upon removal of space-occupying structures from such an implant.

    Low Molecular Weight Immune-Modulators As Adjuvants for Specific Immunotherapy
    9.
    发明申请
    Low Molecular Weight Immune-Modulators As Adjuvants for Specific Immunotherapy 审中-公开
    低分子量免疫调节剂作为特异性免疫治疗的佐剂

    公开(公告)号：US20160271257A1

    公开(公告)日：2016-09-22

    申请号：US15034341

    申请日：2014-06-12

    申请人： PLS-DESIGN GMBH ,  KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN ,  HELMHOLTZ ZENTRUM MÜNCHEN FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT GMBH

    发明人： Reinhold BREDEHORST ,  Thomas GRUNWALD ,  Markus OLLERT ,  Carsten SCHMIDT-WEBER

    IPC分类号： A61K47/34 ,  A61K39/39 ,  A61K9/127

    CPC分类号： A61K47/34 ,  A61K9/06 ,  A61K9/1272 ,  A61K39/39 ,  A61K2039/55555 ,  A61K2039/577

    摘要： The invention relates to a pharmaceutical composition for local modulation of T cell and B cell responses at the site of allergen or antigen presentation, made of one or more preparations comprising one or more antigens or allergens, and a therapeutically effective dose of two or more low molecular weight immune modulators selected from four groups of tolerance-inducing therapeutics comprising inhibitors of complement-mediated functions, inhibitors of tumor necrosis factor receptor 1 (TNFR1)-mediated functions, inhibitors of interleukin 4- and interleukin 13-mediated functions, and therapeutic agents suitable for vitamin D3 supplementation wherein preferably two or more low molecular weight immune modulators and one or more antigens or allergens are coated or adsorbed on or embedded in a matrix, wherein the matrix is selected as to enable sustained release of one or more antigens or allergens and two or more immune modulators for the treatment of T cell-mediated diseases.

    摘要翻译： 本发明涉及由一种或多种包含一种或多种抗原或变应原的制剂以及治疗有效剂量的两种或更多种低分子量的由变应原或抗原呈递位点局部调节T细胞和B细胞应答的药物组合物 选自四组耐受诱导疗法的分子量免疫调节剂，包括补体介导的功能抑制剂，肿瘤坏死因子受体1（TNFR1）介导的功能的抑制剂，白介素4和白细胞介素13介导的功能的抑制剂和治疗剂 适合维生素D3补充，其中优选将两种或更多种低分子量免疫调节剂和一种或多种抗原或过敏原包被或吸附在基质上或嵌入基质中，其中选择基质以使得能够持续释放一种或多种抗原或变应原 和用于治疗T细胞介导的疾病的两种或更多种免疫调节剂。